Browse

Prognostic factors for Korean patients with anaplastic thyroid carcinoma

Cited 53 time in Web of Science Cited 63 time in Scopus
Authors
Kim, Tae Yong; Kim, Kyung Won; Jung, Tae Sik; Kim, Jung Min; Kim, Sun Wook; Chung, Ki-Wook; Kim, Eun Young; Gong, Gyungyub; Oh, Young Lyun; Cho, Soo Youn; Yi, Ka Hee; Kim, Won Bae; Park, Do Joon; Chung, Jae Hoon; Cho, Bo Youn; Shong, Young Kee
Issue Date
2007-02-03
Publisher
Wiley-Blackwell
Citation
Head Neck. 2007 Aug;29(8):765-72.
Keywords
AdolescentAdultAgedAged, 80 and overAnalysis of VarianceCarcinoma/*mortality/*pathology/therapyCombined Modality TherapyDisease-Free SurvivalFemaleHumansKorea/epidemiologyLymphatic MetastasisMaleMedical RecordsMiddle AgedPrognosisRetrospective StudiesRisk FactorsSurvival AnalysisThyroid Neoplasms/*mortality/*pathology/therapyThyroidectomy
Abstract
BACKGROUND: Anaplastic thyroid carcinoma (ATC), although rare, is one of the most aggressive human cancers, and patients with ATC have extremely poor prognoses despite various therapeutic measures. We wished to determine the prognostic factors of survival and effect of treatment on survival rate in patients with ATC. METHODS: We retrospectively reviewed the medical records of the 121 patients (41 men and 80 women) diagnosed with ATC from January 1995 to June 2004 at 5 major referral centers in Korea. RESULTS: Mean patient age at diagnosis was 64 +/- 11 years (range, 17-84 years). Of the 121 patients, 11 (9%) had intrathyroidal tumors, 69 (57%) had extrathyroidal tumors or lymph node involvement, 29 (24%) had distant metastases, and 12 had no data about staging (9%). The mean tumor diameter was 5.5 +/- 2.5 cm (range, 0.5-17.0 cm). At a median follow-up of 41 months (range, 26-122 months), 8 patients were alive. Median survival time was 5.1 months. The disease-specific survival rates were 42% at 6 months, 16% at 12 months, and 9% at 24 months. Sixteen patients (13%) received only supportive care, 25 (21%) received surgery alone, 20 (16%) received radiation treatment or chemotherapy without surgery, and 60 (50%) received surgery plus radiation treatment or chemotherapy. Multivariate analysis showed that age less than 60 years, tumor size less than 7 cm, and lesser extent of disease were independent predictors of lower disease-specific mortality. CONCLUSIONS: Long-term survival is possible for ATC patients less than 60 years old and with small localized tumors. Although aggressive multimodal therapy, including surgery, radiation treatment, and chemotherapy, was not significantly associated with improved survival, we advocate aggressive multimodal therapy in selected ATC patients with good prognostic factors.
ISSN
1043-3074 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17274052

http://hdl.handle.net/10371/27629
DOI
https://doi.org/10.1002/hed.20578
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse